Impact News +++ Enphase sinks as U.S. home solar market seen shrinking by 20% next year (SeekingAlpha) +++ ENPHASE Aktie +3,31%

REPLIMUNE Aktie

>REPLIMUNE Aktienkurs

2.38 EUR +0.0% (Tradegate)

Ask: 2.4 EUR / 1700 Stück

Bid: 2.34 EUR / 855 Stück

Tagesumsatz: 117307 Stück

Realtime Kurs von 8 bis 22 Uhr!

REPLIMUNE Aktie über LYNX handeln

Intraday

1 Jahr

>REPLIMUNE Performance

1 Woche: -77,3%

1 Monat: -70,9%

3 Monate: -68,9%

6 Monate: -81,1%

1 Jahr: -73,9%

laufendes Jahr: -79,9%

>REPLIMUNE Aktie

Name:

REPLIMUNE GR. INC DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US76029N1063 / A2JQN1

Symbol/ Ticker:

7R8 (Frankfurt) / REPL (NASDAQ)

Kürzel:

FRA:7R8, ETR:7R8, 7R8:GR, NASDAQ:REPL

Index:

Webseite:

https://replimune.com/

Marktkapitalisierung:

184.28 Mio. EUR

Umsatz:

EBITDA:

-221.52 Mio. EUR

Gewinn je Aktie:

-2.73 EUR

Schulden:

64.91 Mio. EUR

Liquide Mittel:

94.7 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -14.3%

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / 0.47 / -

Gewinnm./ Eigenkapitalr.:

- / -62.58%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

REPLIMUNE

Letzte Datenerhebung:

23.07.25

>REPLIMUNE Eigentümer

Aktien: 77.09 Mio. St.

f.h. Aktien: 53.03 Mio. St.

Insider Eigner: 4.51%

Instit. Eigner: 107.49%

Leerverk. Aktien: 12.85%

>REPLIMUNE Peer Group

ADDUS HOMECARE

ANAPTYSBIO

ANAVEX

BIO-TECHNE

BROOKDALE

CENTESSA

INTEGER HOLDINGS

OPTHEA ADR

ORTHOPEDIATRICS

US PHYSICAL THERAPY

>REPLIMUNE Chart & Kurs - NASDAQ

>REPLIMUNE News

22.07.25 - 16:24	XFRA: 7R8: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN REPLIMUNE GR. INC DL-,001 7R8 US76029N1063 AB/FROM ONWARDS 22.07.2025 16:12 CET...

22.07.25 - 16:18	FDA Rejects Replimunes Blood Cancer Drug, Stock Sinks (Benzinga)
	Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval. read more...

22.07.25 - 15:24	FDA Rejects Replimune′s Skin Cancer Treatment, Shares Sink (Bloomberg)
	US regulators rejected a skin cancer treatment from Replimune Group Inc. in another sign of the agency's new leadership taking a hard line on drug approvals....

22.07.25 - 13:39	Replimune says FDA rejected its lead drug for skin cancer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.07.25 - 13:18	XFRA: 7R8: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL REPLIMUNE GR. INC DL-,001 7R8 US76029N1063 BAW/UFN...

22.07.25 - 13:16	XFRA: INSTRUMENT_SUSPENSION - EQUBF_01 (XETRA)
	Instrument ID [10351] (7R8 - US76029N1063) suspended...

11.07.25 - 22:03	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....

06.06.25 - 22:03	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....

01.06.25 - 16:03	Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire EN)
	- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions -...

23.05.25 - 07:02	Insiderhandel: Chief Accounting Officer verkauft Aktien von Replimune Group im Wert von 26460 USD (Insiderkauf)
	Schwendenman, Andrew - Vorstand - Tag der Transaktion: 2025-05-20...

23.05.25 - 07:02	Insiderhandel: Chief Commercial Officer verkauft Aktien von Replimune Group im Wert von 30179 USD (Insiderkauf)
	Sarchi, Christopher - Vorstand - Tag der Transaktion: 2025-05-20...

23.05.25 - 07:02	Insiderhandel: Aufsichtsrat verkauft Aktien von Replimune Group im Wert von 260169 USD (Insiderkauf)
	Astley-Sparke, Philip - Aufsichtsrat - Tag der Transaktion: 2025-05-20...

23.05.25 - 07:02	Insiderhandel: Chief Executive Officer verkauft Aktien von Replimune Group im Wert von 202346 USD (Insiderkauf)
	Patel, Sushil - Vorstand - Tag der Transaktion: 2025-05-20...

23.05.25 - 07:02	Insiderhandel: Chief Medical Officer verkauft Aktien von Replimune Group im Wert von 64093 USD (Insiderkauf)
	Xynos, Konstantinos - Vorstand - Tag der Transaktion: 2025-05-20...

23.05.25 - 07:02	Insiderhandel: Chief Financial Officer verkauft Aktien von Replimune Group im Wert von 20407 USD (Insiderkauf)
	Hill, Emily Luisa - Vorstand - Tag der Transaktion: 2025-05-20...

22.05.25 - 13:09	Replimune Group GAAP EPS of -$3.07 misses by $0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.05.25 - 13:03	Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	• BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete...

16.05.25 - 14:03

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day (GlobeNewswire EN)

WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025....

09.05.25 - 22:03	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....

11.04.25 - 22:03	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein Politiker verschweigt oft auch das, was er nicht weiß. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram